Clinical Trial Update: Tivantinib in Treating Patients With Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for tivantinib in metastatic prostate cancer has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer
• Prostate Carcinoma

Drugs mentioned

• tivantinib (tivantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-09-12